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To assess Q fever in France, we analyzed data for 
1985–2009 from the French National Reference Center. 
A total of 179,794 serum samples were analyzed; 3,723 
patients (one third female patients) had acute Q fever. 
Yearly distribution of acute Q fever showed a continuous 
increase. Periodic variations were observed in monthly 
distribution during January 2000–December 2009; cases 
peaked during April–September. Q fever was diagnosed 
more often in patients in southeastern France, where our 
laboratory is situated, than in other areas. Reevaluation of 
the current positive predictive value of serologic analysis 
for endocarditis was performed. We propose a change 
in the phase I (virulent bacteria) immunoglobulin G cutoff 
titer to >1,600. Annual incidences of acute Q fever and 
endocarditis were 2.5/100,000 persons and 0.1/100,000 
persons, respectively. Cases and outbreaks of Q fever have 
increased in France.
Q 
fever is a worldwide zoonosis caused by the 
intracellular bacterium Coxiella burnetii ( 1). Cases 
of Q fever in the United States reported during the second 
Gulf War in Iraq have raised new interest in this disease; Q 
fever is generally considered a forgotten infectious disease 
in developing countries (2). In a study conducted in France 
during 1985–1998, the main symptoms of Q fever were 
classiﬁ   ed. This study also reported monthly incidence; 
peaks in April, May, and June were also identiﬁ  ed (3). 
Furthermore, large outbreaks of Q fever in the Netherlands 
(4) and in a school in Israel (5) during the past 3 years have 
brought attention to the frequency of Q fever.
Q fever is primarily transmitted by cattle, goats, and 
sheep (6). Humans are infected by aerosols from parturient 
ﬂ   uids of infected livestock. C.  burnetii is resistant to 
environmental conditions and can survive for several 
weeks or months in areas where livestock are present. 
These bacteria can also be transmitted by wind (7).
The main characteristic of Q fever is its clinical 
polymorphism. Acute Q fever is deﬁ  ned  as  primary 
infection with C. burnetii, and <60% of infected patients 
may be asymptomatic. However, Q fever can manifest as 
an inﬂ  uenza-like syndrome, pneumonia, or hepatitis, and 
2% of patients with acute disease are hospitalized. Chronic 
Q fever is deﬁ  ned as an infection that lasts 6 months and 
has a phase I (virulent bacteria) immunoglobulin (Ig) titer 
>800. The most common form of chronic Q fever includes 
endocarditis (73%). Its estimated prevalence among cases 
of Q fever is 2%–5% (1). This pathology often occurs when 
patients have underlying valvulopathy. Osteomyelitis, 
vascular infections, and chronic hepatitis have also been 
described (2,8). Serologic proﬁ  les of patients with acute 
and chronic Q fever differ. In the acute form, IgM against 
phase I and phase II (avirulent bacteria) Q fever is observed. 
In the chronic phase, high levels of IgG against both phases 
are observed (9).
Because symptoms of Q fever are nonspeciﬁ  c (10), 
its diagnosis is still based on serologic analysis and 
varies with the attention of the attending physician, true 
prevalence of the disease, and quality of the diagnostic 
tests (2). The deﬁ   nitions of acute and chronic Q fever 
are based on a previous study conducted when testing 
for Q fever was performed infrequently (10). The French 
National Reference Center (NRC) database was created in 
1985. Because Q fever seemed to be rapidly reemerging 
in France, we conducted a study that focused on potential 
causes, seasonality, geographic distribution, and outbreaks 
of the disease.
Patients
At the NRC, specimens from patients with suspected 
Q fever are collected routinely. We used these samples for 
serologic analysis. In cases of endocarditis, heart valves 
were tested by histological analysis, immunohistochemical 
analysis, PCR, or cell culture. Serum samples were 
transported at ambient temperature and valve samples 
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were transported at –80°C. Since 1985, all serum samples 
received have been screened by immunoﬂ  uorescent assay 
by using a large panel of antigens, including those from C. 
burnetii, Rickettsia spp., Bartonella spp., and Francisella 
tularensis. When antibody titers indicated infection with 
C. burnetii, monitoring was proposed with a serologic 
control 3 weeks after the ﬁ  rst sample. However, for this 
study, only the ﬁ  rst positive serum sample was used to 
determine whether Q fever showed a seasonal distribution 
and to evaluate the incidence of Q fever. For each patient, 
geographic origin, sex, age, and test results were added to 
1 database.
Every year, the NRC provides an activity report in 
which annual data are analyzed. For Q fever, the number 
of positive serum samples and the total number of serum 
tested are included. The report describes the number of 
acute and chronic Q fever cases for the year.
Q fever seasonality and geographic distribution during 
January 2000–December 2009 were analyzed. We also 
classiﬁ  ed all patients during 2009 on the basis of 2 criteria: 
1)  ﬁ  rst positive serologic result in 2009 and 2) clinical 
status of the patient in the database. This classiﬁ  cation was 
performed to evaluate incidence of endocarditis according 
to serologic titer and modiﬁ  ed Duke Criteria. Patients were 
classiﬁ  ed as having deﬁ  nite or possible endocarditis (11).
Serologic Analysis
Antigens were prepared for testing of phase I and 
II samples as described (10). Serum samples were ﬁ  rst 
screened at dilutions of 1:25, 1:50, and 1:100 by using an 
indirect immunoﬂ   uroescent antibody (IFA) test. Serum 
samples positive for total antibodies against Q fever at 
1:100 dilution were tested by IFA to determine the IgG, 
IgM, and IgA titers for phases I and II. Serum with a 
phase II IgG titer >200 and a phase II IgM titer >50 was 
predictive for acute Q fever. This serologic criterion was 
used to deﬁ  ne acute Q fever. If a phase I IgG titer was 
>800, chronic Q fever was suspected, which depended on 
other clinical ﬁ  ndings. A low level of IgG is considered 
evidence of past infection (12).
Statistical Analysis
Since 1991, serologic results have been entered into 
our laboratory database and can be extracted as Excel 
(Microsoft, Redmond, WA, USA) ﬁ  les. Excel sheets were 
analyzed by using PASW Statistics software version 17.0 
(SPSS Inc., Chicago, IL, USA). Seasonality of acute Q 
fever during January 2000–December 2009 was studied by 
using Expert Modeler (SPSS Inc.). This software identiﬁ  ed 
the best model to use to analyze the data. Dependent 
variable series were also analyzed by using Expert 
Modeler, which automatically generates the best-ﬁ  tting 
seasonal or nonseasonal model. This software also provides 
a better understanding of the data and predictions for future 
points in the series. Stationary R2 goodness was used to 
measure the level of compliance of the data compared with 
the theoretical model. The Ljung-Box test (http://www.
itl.nist.gov/div898/software/dataplot/refman1/auxillar/
ljungbox.htm) was used to test the null hypothesis that 
autocorrelations of the residual time series were equal to 
0. Statistical analyses of geographic distribution, mean 
age, and sex were conducted by using Epi Info version 6 
(Centers for Disease Control and Prevention, Atlanta, GA, 
USA).
Evolution of Q Fever
During January 1985–December 2009, a total of 
179,794 serum samples were analyzed (Table 1, Figure 1); 
39,472 (30%) were positive, i.e., positive for antibodies at 
the ﬁ  rst screening at a 1:100 dilution; 3,723 patients had 
acute Q fever (phase II IgG titer >200 and phase II IgM 
titer >50), and 1,675 had chronic Q fever (phase I IgG titer 
>800). The number of serum samples analyzed increased 
each year (except in 2006 and 2007), from 2,290 in 1985 to 
12,443 in 2009. The number of positive serum samples also 
increased; peaks occurred in 1992 and in 2004. In 2004, the 
increase in serum samples positive for Q fever showed a 
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Table 1. Serum samples tested for Q fever, by year, France* 
Year 
No. positive/ 
no. tested (%) 
No. positive 
Acute disease  Chronic disease
1985 239/2,290  (10.4)  22 8
1986 518/3,464  (15.0)  37 8
1987 767/4,361  (17.6)  52 12
1988 706/3,403  (20.7)  49 12
1989 1,316/4,258  (30.9)  40 18
1990 1,621/4,720  (34.3)  92 22
1991 1,737/5,028  (34.5)  112 20
1992 2,011/5,249  (38.3)  89 29
1993 1,815/7,020  (25.9)  76 26
1994 1,472/7,222  (20.4)  102 24
1995 1,359/6,171  (22.0)  73 34
1996 1,326/7,101  (18.7)  116 28
1997 1,683/7,050  (23.9)  70 35
1998 1,420/7,340  (19.3)  140 37
1999 1,537/8,296  (18.5)  199 32
2000 1,460/8,444  (17.3)  135 32
2001 1,589/8,974  (17.7)  167 38
2002 2,029/10,639  (19.1)  224 55
2003 2,094/10,588  (19.8)  242 52
2004 2,544/10,742  (23.7)  360 70
2005 2,514/10,597  23.7)  199 100
2006 2,010/7,891  (25.5)  266 237
2007 1,700/5,522  (30.8)  244 278
2008 2,073/10,981  (18.9)  256 263
2009 1,933/12,443  (15.5)  361 205
Total 39,472/179,794 (21.9)  3,723  1,675 
*Acute disease, phase II (avirulent bacteria) immunoglobulin (Ig) G titer 
>200 and phase II IgM titer >50; chronic disease, phase I (virulent 
bacteria) IgG titer >800.SYNOPSIS
correlation with increases in acute and chronic Q fever; 114 
cases of acute Q fever were diagnosed in the Marseille area. 
Of the patients with acute Q fever, we had data for 919 
(33.8%) female patients and 1,799 (66.2%) male patients.
Cases of acute Q fever increased continuously during 
1985–2009 (Figure 2). The number of patients with 
serologic results for Q fever was stable; <100 cases were 
detected per year until 2004. Subsequently, >200 cases 
were diagnosed every year because physicians obtained 
more samples from patients for follow-up of acute infection 
(Figure 2).
The monthly distribution of acute Q fever during 
January 2000–December 2009 was determined. Variations 
in number of acute Q fever cases periodically occurred 
(Figure 3). Infections peaks occurred every year during 
April–September. Lower infection rates occurred during 
October–January. No peaks were observed in 2003 or 
2005, which had <30 cases per month. The highest value 
was observed in June 2009 and was related to the outbreak 
in Cholet and to cases in Bouches du Rhône.
The Autoregressive Integrated Moving Average 
model selected by the Expert Modeler found a good 
correlation between observed and predicted values and 
also demonstrated an ability to predict peaks of infections. 
The stationary R2 goodness-of-ﬁ  t obtained with this model 
indicated that 49% of the variation in the number of acute 
Q fever cases was explained by the model (i.e., the month, 
which is the variable in our model, explained 49% of 
the ﬂ  uctuation in the rate of Q fever rate). However, the 
Ljung-Box test value of 0.034 suggested that patterns in the 
observed series were not accounted for in the model.
Data regarding geographic distribution were obtained 
during January 1, 2000–December 31, 2009 (Figure 4). 
Geographic origin was known for 2,048 of 2,798 patients; 
data for 750 (26%) patients were missing. A total of 907 
patients with Q fever were living in Provence Alpes Côte 
d’Azur, the region in which the NRC is located. The 
incidence of Q fever in this region was 19 cases/1 million 
inhabitants/y. Rhône-Alpes and Poitou-Charentes each had 
12.7% of the cases. Incidence of cases in other regions did 
not exceed 6% (Figure 4).
Patient age was recorded for 2,658 patients during 
2000–2009. The mean ± SD age was 46.2 ± 16.8 years, and 
the median age was 45 years (range 0–93 years). The mean 
± SD age was 44.9 ± 18 years (median 43 years, range 
<1–90 years) for female patients and 46.8 ± 16.14 years 
(median 46 years, range 1–93 years) for male patients. The 
difference in mean age between male and female patients 
was signiﬁ  cant (p = 0.0072).
In 2009, we obtained clinical information for 325 
patients with positive serologic results. For this study, we 
classiﬁ  ed the patient only if we obtained echocardiographic 
results for each patient. This process resulted in data for 
172 patients according to the modiﬁ  ed Duke Criteria (11). 
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Figure 1. Serum samples tested for Q fever, 
France, 1985–2009. A) Black line indicates 
no. positive. B) Black line indicates % 
positive for acute Q fever. Q Fever in France, 1985–2009
We classiﬁ  ed these 172 patients according to their phase 
I IgG titers and identiﬁ  ed 4 possible cases of endocarditis 
and 0 deﬁ  nite cases of endocarditis in patients whose phase 
I IgG titers were <800. For patients with phase I IgG titers 
≥800, 1,600, 3,200 and 6,400, the numbers of deﬁ  nite cases 
of endocarditis were 41, 32, 24, and 17, respectively, and 
the numbers of possible cases of endocarditis were 11, 
9, 3, and 1, respectively. The positive predictive values 
(PPVs) of IgG1 serologic results for possible or deﬁ  nite 
endocarditis were 37%, 59%, 57%, and 75% at titers of 
800, 1,600, 3,200 and >6,400, respectively (Table 2).
Reemergence?
In this study, we demonstrated an increase in the 
yearly incidence of acute Q fever. Although we observed 
a clear trend of increased testing (Table 1), the data also 
showed an increase in the percentage positive among 
the samples being tested, increasing from 1% in 1989 to 
3%–4% in 2005–2009 (Figure 1). These ﬁ  ndings suggest 
several interpretations of this increased incidence. One 
interpretation could be improved diagnostic capability 
caused by development and availability of commercial 
diagnostic tests. At this stage, only ELISAs (Panbio, 
Sinnamon Park, Queensland, Australia, and Virion/Serion, 
Würzburg, Germany) and immunoﬂ  uorescent  assays 
(Focus Diagnostics, Cypress, CA, USA) are available. In 
our laboratory, in addition to PCR, an in-house method 
based on an IFA has been used for Q fever diagnosis since 
1985. The continuity of our techniques enables comparison 
of results. Ake et al. demonstrated heterogeneous serologic 
results that depended on the method used (13). They 
focused on the necessity of having a reference laboratory to 
reduce potential interlaboratory and interassay variability.
Despite the increasing number of serum samples 
received by the NRC, our collection was insufﬁ  cient 
to accurately determine the incidence of Q fever in 
France. In the United States, surveillance for this disease 
has historically been limited, and only 436 cases were 
reported during 1978–1999. In 1999, Q fever became a 
reportable disease in the United States, and the number 
of cases increased by 250% during 2000–2004 because of 
improved recognition and reporting (14). This study shows 
the need for national surveillance and conﬁ  rms that lack of 
interest in the disease has consequences when incidence is 
determined.
Outbreaks of Q fever in France contributed to 
increases in incidence in 1987, 1996, 2002–2003, and 2009. 
However, incidence can be determined only if physicians 
are aware of Q fever. In 1987, forty cases of acute Q 
fever were diagnosed at a psychiatric institution in Banon, 
France (15). This outbreak affected patients and staff who 
worked on a farm where goats were raised for milk and 
cheese production. An outbreak was also reported in 1996 
in Briançon, France, where 29 cases of acute Q fever were 
identiﬁ  ed (16). Analysis of risk factors in a case–control 
study suggested that transmission resulted from airborne 
contaminated sheep waste, which had been left uncovered 
in a slaughterhouse area. Another outbreak was detected 
in 2002 in Chamonix, France, in which 101 patients were 
diagnosed with acute Q fever during August 30, 2002–July 
31, 2003 (17). The most recent outbreak in France was at 
an abattoir in Cholet in 2009, in which 50 cases of acute 
Q fever were detected and conﬁ  rmed (D. Raoult, unpub. 
data).
Outbreaks in the Netherlands during the past 3 
years (182, 1,000, and 2,361 cases in 2007, 2008, and 
2009, respectively) have emphasized the need to detect 
Q fever in livestock, particularly in goats (4). When 
infected animal fetuses are aborted, massive amounts of 
microbes are released. Goats and other infected animals 
are predominantly asymptomatic, which makes Q fever 
difﬁ   cult to detect. Investigations in the Netherlands 
showed that outbreaks in 2007, 2008, and 2009 started in 
≈2005. Measures taken in this country included massive 
vaccination of goats with an animal vaccine produced by 
CEVA (Libourne, France). Although this vaccine does 
not prevent all infections and is not effective in infected 
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Figure 2. Cases of chronic (white bars) and acute (black bars) 
Q fever, France, 1985–2009. Locations where outbreaks were 
reported are indicated by arrows. 
Figure 3. Seasonality of acute Q fever cases, France, 2000–2009. SYNOPSIS
animals, it does prevent most abortions. Therefore before 
vaccination, farmers must kill all pregnant goats on affected 
farms, regardless of the vaccination status of the animals. 
However, although outbreaks were a factor in the increase 
in Q fever, they were likely not the sole cause of increases 
in recent years.
Another reason for the increase in incidence of Q 
fever was increased interest of physicians in this disease. 
Results from a survey showed that the highest incidence 
of this disease in France was in Bouches du Rhône, where 
our laboratory is located. The proximity of the NRC has 
been suggested to inﬂ  uence the number of cases detected 
in this area; the annual incidence in our area (19 cases/1 
million persons) was much higher than in the rest of France 
(3 cases/1 million persons). However, other reasons may 
explain changes in the geographic distribution of this 
disease.
Van der Hoek et al. reported the distribution of Q 
fever in humans in the Netherlands in 2009; a total of 
59% of the cases were in persons who lived within a 5-km 
radius of an infected dairy sheep or dairy goat farm (12% 
of the population lived in these areas). The incidence was 
69 cases per 100,000 persons in those who lived within a 
5-km radius of infected livestock and 6 cases per 100,000 
persons in those who lived outside the 5-km radius 
(18). Angelakis and Raoult reported that contaminated 
aerosols are the major mechanism for transmission of C. 
burnetii to humans (19). Data for 2008 from the French 
Agriculture Ministry (www.agreste.agriculture.gouv.fr) 
indicate that regions with the highest incidence of acute 
Q fever are regions with the highest number of cattle, 
sheep, and goats. Provence Alpes Côte d’Azur, the region 
in which the largest number of cases was detected, ranks 
fourteenth among French regions for number of livestock. 
Rhône-Alpes and Poitou Charente rank twelfth and sixth, 
respectively. Midi-Pyrénées, which contains the largest 
number of livestock, accounted for only 1.1% of acute Q 
fever cases in France.
Analysis of the monthly distribution of acute Q fever 
showed seasonality of the disease. Several factors might 
account for this phenomenon. C.  burnetii is present in 
aerosols of parturient ﬂ   uids from infected animals (1). 
Tissot-Dupont et al. reported seasonal increases in April and 
June (20) that were not correlated with sheep birth, which 
occurs in October. This observation could be explained 
by an increased number of lambs killed for Easter. Tissot-
Dupont et al. also reported the role of wind in transmitting 
C. burnetii (7); an increase in incidence of Q fever during 
winter of 1998–99 correlated with increased velocity 
of mistral (the wind in southern France). These authors 
reported fewer cases of Q fever occurred in mountainous 
areas than in plains (20). A study in the United Kingdom 
demonstrated the role of airborne transmission (21). 
Hellenbrand et al. analyzed cases of Q fever in Germany 
during 1962–1999 (22). They found an irregular cyclic 
incidence pattern, but did not distinguish between acute 
and chronic forms of the disease. They also reported a 
change in community outbreak seasonality in Germany: 
a marked decrease in winter and an increase in summer. 
These changes coincide with decreases in nomadic sheep 
farming. These authors concluded that the incidence of Q 
fever has increased in Germany.
The number of patients in France with a chronic Q 
fever serologic proﬁ  le has increased since 2006. However, 
with an average of 67 cases of chronic Q fever detected 
per year during 1985–2009, we expected to identify 50% 
of the chronic disease cases in France. Our data are more 
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Figure 4. Geographic distribution of acute Q fever cases, France, 
2000–2009. Values and scale bar indicate % prevalence.
Table 2. PPV of Q fever phase I IgG titers for patients with endocarditis, France, 2009* 
Characteristic
Titers
>800 >1,600 >3,200 >6,400 
No. with definite endocarditis  41 32 24 17
No. with possible endocarditis  11 9 3 1
Total 141 88 47 24
PPV, % (definite or possible endocarditis)  37 59 57 75
*PPV, positive predictive value; phase I, virulent bacteria; Ig, immunoglobulin. Q Fever in France, 1985–2009
comprehensive because the NRC is the only laboratory that 
analyzes the phase I antibodies against Q fever in France.
Criteria for diagnosis of chronic Q fever were 
established in 1994 (10). Before this study, the PPV was 
determined by using Bayes theorem, and patients with 
endocarditis were tested for Q fever. The PPV for phase 
I IgG titers of 800 and 1,600 was high (98.1% and 100%, 
respectively). When we analyzed data from 2009, the PPV 
for possible or deﬁ  nite Q fever endocarditis (Table 2) was 
37% for patients with phase I IgG titers >800 and 75% for 
patients with phase I IgG titers >6,400. This difference 
between the 2 studies reﬂ  ects the increasing number of 
samples tested. In 2009, we diagnosed 41 deﬁ  nite and 11 
possible cases of endocarditis caused by C.  burnetii. A 
study published in 2000 with NRC data for 1985–1998 
reported 259 cases of Q fever endocarditis and a mean of 
20 cases per year (3).
The serum collection at the NRC is more comprehensive 
than it was 10 years ago, which could explain the increase 
in the number of cases. We believe that the number of C. 
burnetii endocarditis cases diagnosed at the NRC represents 
50%–80% of the Q fever endocarditis cases in France. These 
data conﬁ  rm previous data from which the prevalence of Q 
fever endocarditis in the general population in France was 
estimated to be 1 case/1 million persons/y. Several studies 
have estimated that 3%–5% of symptomatic C. burnetii 
infections cause endocarditis (1). These data enabled us to 
estimate the minimum incidence of mild-to-severe acute Q 
fever to be 20 cases/1 million persons/y, which is similar to 
that observed in Provence-Alpes-Côte d’Azur (19 cases/1 
million persons/y) but lower than that observed in Bouches 
du Rhône (40 cases/1 million persons/y in 2009). When 
no outbreak is observed, the incidence of cases diagnosed 
in France at the NRC reﬂ  ects the true incidence of acute 
infections.
Q fever has been recognized since the 1930s. We 
believe that its increased frequency in recent years is a 
combination of an increase in the disease (reemergence), 
growing interest among physicians, better diagnosis in 
laboratories, and more complete data. Monthly analysis of 
the past decade demonstrates the seasonality of Q fever, 
which shows peaks during April–September in Europe. 
We propose a change in the phase I IgG cutoff titer for 
detection of Q fever endocarditis to >1,600; this change 
corresponds to a PPV of 59%. This adjusted cutoff value 
may increase detection of endocarditis in patients with 
a diagnosis of chronic Q fever. Finally, the number of 
identiﬁ  ed epidemics in France and Europe is increasing. 
Increased surveillance of the disease is the only way to 
determine the effects of Q fever.
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